😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Nearly 4 million Americans received updated COVID boosters last week - CDC

Published 10/06/2022, 05:02 PM
Updated 10/06/2022, 11:01 PM
© Reuters. Colleen Dempsey, 54, receives the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022.  REUTERS/Hannah Beier/File Photo
PFE
-
MRNA
-

(Reuters) -Around 3.9 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.

The CDC said a total of 11.5 million Americans had received the shot as of Oct. 5, the first five weeks the booster has been available. This is up from the 7.6 million people who received the shot as of Sept. 28.

The 11.5-million figure represents only 5.3% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series.

The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people. Around 20 million people received their third shot in the first five weeks of that vaccination campaign.

A recent survey conducted by the nonprofit Kaiser Family Foundation found that nearly two-thirds of adults in the United States do not plan to get updated COVID-19 booster shots soon.

The U.S. Food and Drug Administration authorized Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA)'s Omicron-tailored shots in August in preparation for the country's ongoing fall revaccination campaign.

The CDC tally includes booster shots from both Pfizer/BioNtech and Moderna.

© Reuters. Colleen Dempsey, 54, receives the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022.  REUTERS/Hannah Beier/File Photo

While the Pfizer/BioNTech updated COVID-19 booster is approved for those aged 12 and above, Moderna's shot is approved for individuals aged 18 and above.

These Omicron-tailored shots aim to tackle the BA.5 subvariants, which makes up a significant majority of the currently circulating variants in the United States, according to government data. These shots are expected to also be effective against the slowly rising BA.4.6 subvariant.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.